NOWDiagnostics First To Know® Syphilis Test Receives FDA De Novo Marketing Authorization

NOWDiagnostics, Inc. (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization to its First To Know® Syphilis Test for OTC use. First To Know® is the first and only rapid syphilis test in the U.S. that provides an in-home result in 15 minutes with a single drop of blood. It has been proven in a clinical study of 1,270 people to be easy to use. The test received marketing authorization from the FDA through the de novo pathway, recognizing it as a novel device for syphilis testing in the United States, distinguishing it from other products on the market.

Kompass Kapital named a 2024 BEST PLACES TO WORK Honoree by KCBJ

Best Places to Work

For our Best Places to Work honorees, culture is king. They’ve built an environment where employees feel engaged and valued, they trust the leadership and have opportunities to learn and advance their careers.

Past honorees have offered perks, such as daily fresh lunches at no cost to employees, a social committee that plans events, child care reimbursement and a maternity management program that supports expectant mothers with nine months of health coaching and postpartum assessment.

But don’t think it’s the companies that do the bragging. For this awards program, the employees provide the insights about their workplace.